Towards ethical drug pricing: the European Orphan Genomic Therapies Fund.
Gene Ther
; 31(7-8): 353-357, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38658672
ABSTRACT
An increasing number of novel genomic therapies are expected to become available for patients with rare or ultra-rare diseases. However, the primary obstacle to equal patient access to these orphan genomic therapies are currently very high prices charged by manufacturers in the context of limited healthcare budgets. Taking into account ethical pricing theories, the paper proposes the implementation of a pricing infrastructure covering all European member states, which has the potential to promote distributive justice while maintaining the attractiveness of genomic therapy development.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Produção de Droga sem Interesse Comercial
/
Terapia Genética
/
Doenças Raras
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
En
Revista:
Gene Ther
Assunto da revista:
GENETICA MEDICA
/
TERAPEUTICA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Alemanha